Blue Sky Alternative Investments Limited (ASX:BLA) is currently trading at a trailing P/E of 8.6x, which is lower than the industry average of 18.2x. While this makes BLA appear like a great stock to ...

bluebird bio, Inc. BLUE announced that the FDA has granted priority review to the biologics license application (BLA) seeking approval for elivaldogene autotemcel (eli-cel, Lenti-D) to treat cerebral ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Before it collapsed, the ASX-listed asset manager had put millions into a private equity group that owned the Boston beer operation. It hasn’t gone well. Another class action lawsuit has been lobbed ...

bluebird bio BLUE announced that the FDA has extended the review period of biologics licensing applications (BLAs) for betibeglogene autotemcel (beti-cel) and elivaldogene autotemcel (eli-cel) as ...